Sign up
Pharma Capital

PreveCeutical awarded default judgement on civil claim in British Columbia

The health sciences company received a judgement against JCN Capital Corp
judge's gavel
The company argued that the defendants failed to provide PreveCeutical with agreed-upon consulting services and subscription agreements

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) obtained a default judgement in a Supreme Court of British Columbia civil case, the company announced Monday.

The health sciences company received a default judgement against JCN Capital Corp in connection with a case brought by PreveCeutical alleging fraudulent misrepresentation, breach of contract, conspiracy, unjust enrichment and breach of duty of honest performance.

READ: PreveCeutical gets default judgement in part of civil claim

The Vancouver-based company argued that the defendants failed to provide PreveCeutical with agreed-upon consulting services and subscription agreements.

"We are pleased to have received this third default judgement as it demonstrates that PreveCeutical is actively pursuing this action," said PreveCeutical Chairman and CEO Stephen Van Deventer in a statement.

The amount of damages and costs awarded to PreveCeutical are still being assessed by the court.

The company continues to pursue other civil cases in the courts, according to a statement.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

1553005391_Angela2.jpg
Why Invest In PreveCeutical Medical Inc? Read More Here

Register here to be notified of future PREV Company articles
View full PREV profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.